AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that
Anthony S. Marucci, interim President and Chief Executive Officer of
AVANT Immunotherapeutics, Inc., will present at the 28th
Annual Canaccord Adams Global Growth Conference at the InterContinental
Hotel in Boston on Wednesday, August 13 at 4:00 pm, EDT.
A live webcast of the company presentation will be available in the
Investor Information area of AVANT’s website
at http://www.avantimmune.com.
An archive of the webcast will be available via AVANT’s
website following the event.
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. is a NASDAQ-listed company discovering
and developing innovative vaccines and targeted immunotherapeutics for
the treatment of cancer, infectious and inflammatory diseases. AVANT
focuses on the use of tumor-specific targets and human monoclonal
antibodies (mAbs) to precisely deliver therapeutic agents through its
novel “targeted immunization”
approach. In addition, AVANT is also exploiting its access to
proprietary human antibody technology for development of therapeutics
monoclonal antibodies (mAbs). AVANT’s deep
product pipeline consists of products in varying stages of development,
with its lead candidate, CDX-110, partnered with Pfizer, Inc., currently
undergoing evaluation in a Phase 2/3 clinical trial in newly diagnosed
glioblastoma multiforme, one of the most aggressive forms of brain
cancer. AVANT also has five product candidates in its development
pipeline including:
CDX-1307, a product based on its proprietary APC Targeting Technology™,
which is in two Phase 1 clinical trials for patients with advanced
pancreatic, bladder, breast and colon cancer;
TP10, a complement inhibitor, in development for transplantation and
other indications; and
Three candidates based on its oral, rapidly-protecting, single-dose
and temperature-stable vaccine technology, including combination
vaccines for travelers, the military and global health needs.
AVANT licensed a rotavirus strain to GlaxoSmithKline that was used in
the development of Rotarix®
for the prevention of rotavirus infection. In addition, AVANT has two
human food safety vaccines for reducing salmonella infection in chickens
and eggs which have been commercialized. Additional information on AVANT
Immunotherapeutics, Inc. can be obtained through its site on the World
Wide Web: http://www.avantimmune.com.
.gif)
